The combination of lapatinib + capecitabine (protocol_1) was one of the common recommended regimens for patients with HER2(+) breast cancer with prior treatment of taxanes, anthracyclines, and/or trastuzumab (29, 30). The gene discussed is ERBB2; the disease is breast carcinoma.